- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00209534
A Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy
December 3, 2009 updated by: Eisai Inc.
A Phase 2, Two Part Study of AQUAVAN® Injection in the Presence of Pre-Medication in Patients Undergoing Elective Colonoscopy
This study was designed to assess the safety and efficacy of AQUAVAN® Injection in providing adequate sedation in patients undergoing colonoscopy.
Prior to the procedure, patients received fentanyl citrate for pain management followed five minutes later by AQUAVAN® Injection for sedation.
Throughout the procedure, study personnel assessed the patient's vital signs and depth of sedation.
After the procedure, the patient, physician, and an evaluator were asked to complete satisfaction surveys.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Randomized, open label, multi-center, adaptive dose ranging study, in which several dose levels of AQUAVAN® Injection and fentanyl citrate injection will be investigated to produce a desired sedation level in patients undergoing elective colonoscopy.
A desired sedative dose/dose range and dosing paradigm will be identified based on pre-set criteria using the Modified Observer's Assessment of Alertness/Sedation (OAA/S).
The desired sedative dose/dose range and dosing paradigm of AQUAVAN® Injection is defined as one that consistently provides mild to moderate sedation (Modified OAA/S between 2 and 4 inclusive) in a majority of patients who are pre-medicated with fentanyl citrate injection.
Study Type
Interventional
Enrollment
200
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients provided written informed consent after receiving a full explanation of the extent and nature of the study.
- Patients were >=18 years of age to ≤60 years (a subset of up to 50 patients >60 years and <85 years of age was allowed).
- Patients, if female, were surgically sterile, postmenopausal or non-pregnant using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose.
- Body mass index (BMI) between 20 and 28.
- Body weight between 50 kg and 100 kg.
- Patients had an ASA Physical Classification System status of I or II;
- Patients required an elective colonoscopy procedure that was anticipated to be performed in <60 minutes (i.e., procedure was predicted to be uncomplicated); desired sedation for the colonoscopy procedure; and were determined by the Investigator to be physically capable of maintaining an adequate airway during mild-to-moderate sedation.
Exclusion Criteria:
- Patients ingested benzodiazepines or barbiturates within 14 days of study start, with the exception of phenobarbital, which required a 21-day washout.
- Patients ingested opioids within 72 hours of study start.
- Patients had current symptoms of upper respiratory infection.
- Patients had a history of allergic reaction or hypersensitivity to any anesthetic agent, narcotic, or benzodiazepine.
- Patients had current signs of significant hiatal hernia, esophageal reflux, or heartburn which, in the opinion of the Investigator, could interfere with maintenance of an adequate airway.
- Patients had a history of alcohol or drug abuse within the past 12 months;
- Patients ingested alcohol or caffeine within 12 hours prior to admission into the study.
- Patients participated in an investigational drug study within 1 month prior to study start.
- Patients were unwilling to adhere to preprocedural and postprocedural instructions.
- Patients donated >300 mL of blood within 1 month prior to study start; or
- Patients were exposed to AQUAVAN in a previous clinical trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
The primary efficacy objective was to determine the desired sedative dose/dose range and dosing paradigm of AQUAVAN, defined as one that consistently provided mild-to-moderate sedation (Modified OAA/S >=2 and <=4) in a majority of patients.
|
Secondary Outcome Measures
Outcome Measure |
---|
Efficacy variables included: time to sedation, time to Fully Alert, time to Fully Recovered, time to Ready for Discharge, Modified OAA/S scores over time, number of doses and amount of AQUAVAN, and Patient and Physician Satisfaction Surveys.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Study Director: James Jones, MD,PharmD, Eisai Inc.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2003
Study Completion (Actual)
February 1, 2004
Study Registration Dates
First Submitted
September 13, 2005
First Submitted That Met QC Criteria
September 13, 2005
First Posted (Estimate)
September 21, 2005
Study Record Updates
Last Update Posted (Estimate)
December 4, 2009
Last Update Submitted That Met QC Criteria
December 3, 2009
Last Verified
December 1, 2009
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 3000-0207
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Colonoscopy
-
Borland-Groover ClinicValley Medical Products, LLC is paying for the study and is the sponsor....CompletedColonoscopy | Screening Colonoscopy | Surveillance ColonoscopyUnited States
-
Josue AliagaCompleted
-
Endostart srlCompleted
-
Rambam Health Care CampusUnknownInadequate Preparation for Colonoscopy; Personalized Colonoscopy PreparationIsrael
-
Hospital Central Norte PEMEXRecruitingPerformance of Colonoscopy | Tolerance of ColonoscopyMexico
-
VA Office of Research and DevelopmentVA Palo Alto Health Care System; VA Northern California Health Care SystemCompletedWater Exchange Colonoscopy | Unsedated Colonoscopy | Cap | Colonoscopy PainUnited States
-
Dalin Tzu Chi General HospitalCompletedColonoscopy | Intubation Time | Cap-assisted ColonoscopyTaiwan
-
Valduce HospitalCompletedUnsedated Colonoscopy | Warm Water | CO2 ColonoscopyItaly
-
Kartal Kosuyolu Yuksek Ihtisas Education and Research...UnknownColonoscopy | Complete Colonoscopy | Cecum Intubation Time | İleum Intubation TimeTurkey
-
Daewoong Pharmaceutical Co. LTD.Not yet recruiting
Clinical Trials on fospropofol disodium
-
West China HospitalCompleted
-
Eisai Inc.CompletedIntubation | Respiration, Artificial | Postoperative SedationUnited States
-
Eisai Inc.CompletedAnesthesia | BronchoscopyUnited States
-
Eisai Inc.PPD; Covance; Quest Pharmaceutical ServicesTerminated
-
Eisai Inc.PPD; Covance; Quest Pharmaceutical ServicesTerminated
-
Eisai Inc.PPD; MDS Pharma Services; Bio Analytical Research Corporation; Coghlan Group (Plasma...CompletedColonoscopy | Colon Polyps
-
Eisai Inc.PPD; CovanceCompletedAngioplasty | Coronary Catheterization
-
Eisai Inc.PPD; CovanceTerminatedOsteotomy | Carpal Tunnel | Arthroscopy | Bunionectomy
-
Eisai Inc.CompletedProcedural SedationUnited States